Biogened S.A.

WSE:BGD Rapporto sulle azioni

Cap. di mercato: zł54.0m

Biogened Performance dei guadagni passati

Il passato criteri di controllo 4/6

Biogened ha registrato una crescita degli utili a un tasso medio annuo di 31%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 12.9%. I ricavi sono stati in crescita a un tasso medio annuo di 19.3%. Il ritorno sul capitale proprio di Biogened è 12.4% e ha margini netti di 4.5%.

Informazioni chiave

31.0%

Tasso di crescita degli utili

33.2%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore29.4%
Tasso di crescita dei ricavi19.3%
Rendimento del capitale proprio12.4%
Margine netto4.5%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Recent updates

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

Ripartizione dei ricavi e delle spese

Come Biogened guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

WSE:BGD Ricavi, spese e utili (PLN Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 241075640
30 Jun 241065610
31 Mar 241004580
31 Dec 23965550
30 Sep 23924470
30 Jun 23904460
31 Mar 23854450
31 Dec 22803420
30 Sep 22774410
30 Jun 22724360
31 Mar 22703360
31 Dec 21652350
30 Sep 21572330
30 Jun 21542330
31 Mar 21501300
31 Dec 20481300
30 Sep 20492290
30 Jun 20481290
31 Mar 20481290
31 Dec 19471280
30 Sep 19451280
30 Jun 19441270
31 Mar 19411260
31 Dec 18401260
30 Sep 18391240
30 Jun 18391240
31 Mar 18361220
31 Dec 17341210
30 Sep 17301190
30 Jun 17311200
31 Mar 17291190
31 Dec 16291190
30 Sep 16322210
30 Jun 16312200
31 Mar 16313190
31 Dec 15303180
30 Sep 15302180
30 Jun 15261150
31 Mar 15241140
31 Dec 14231130
30 Sep 14201120
30 Jun 14211120
31 Mar 14221130
31 Dec 13222120

Guadagni di qualità: BGD ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di BGD (4.5%) BGD sono più alti rispetto allo scorso anno (4.1%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di BGD sono cresciuti in modo significativo del 31% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di BGD nell'ultimo anno ( 28.6% ) è inferiore alla media quinquennale ( 31% all'anno).

Guadagni vs Settore: La crescita degli utili BGD nell'ultimo anno ( 28.6% ) ha superato la percentuale del settore Pharmaceuticals 8.9%.


Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 12.4% ) di BGD è considerato basso.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate